التفاصيل البيبلوغرافية
| العنوان: |
Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw. |
| المؤلفون: |
Paulo, Siri, Laranjo, Mafalda, Abrantes, Ana M., Casalta-Lopes, João, Santos, Kathleen, Gonçalves, Ana C., Paula, Anabela Baptista, Marto, Carlos Miguel, Sarmento-Ribeiro, Ana Bela, Carrilho, Eunice, Serra, Arménio, Botelho, Maria F., Ferreira, Manuel M. |
| المصدر: |
Materials (1996-1944); Jun2019, Vol. 12 Issue 11, p1840, 1p, 1 Black and White Photograph, 2 Diagrams, 1 Chart, 6 Graphs |
| مصطلحات موضوعية: |
CALCIUM phosphate, THERAPEUTICS, OSTEONECROSIS, CALCIUM compounds, DRUG side effects, BONE cells |
| مستخلص: |
(1) Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is one of the most often seen side effects in patients treated with nitrogen-containing bisphosphonates (BPs), a post-surgical non-healing wound condition. Since calcium phosphate (CP) compounds are able to adsorb zoledronate (ZOL) when used as a drug delivery vehicle, we aimed to verify if these ceramics might have a potential protective effect for soft tissues surrounding surgical osseous wounds. (2) Methods: The chemical reaction between ZOL and CP compounds was evaluated through ultraviolet-visible spectroscopy and elemental analysis. A primary culture of human gingival fibroblasts (HGF) was established as a model to evaluate the cytotoxicity of the association of ZOL (5–500 μM) and of ZOL/biphasic calcium phosphates (BCP). Metabolic activity, cell viability, types of cell death, the cell cycle through, and the migration ability of human gingival fibroblasts were evaluated. (3) Results: ZOL was adsorbed by biphasic calcium phosphate compounds in an aqueous solution. The HGF were sensitive to ZOL toxicity; nevertheless, ZOL/BCP showed a significant protective effect regarding metabolic activity, cell viability, and cell migration. (4) Conclusions: BCP interaction with ZOL reduces or abolishes its toxicity in HGF. This finding represents a potential solution for BRONJ in the case of patients undergoing therapy with ZOL. [ABSTRACT FROM AUTHOR] |
|
Copyright of Materials (1996-1944) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder